Article

Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for both

2022-10-13

Abstract excerpt

<h4>Background: </h4> Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of severe adult asthma patients eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods This was a prospective cohort study that inc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1e0e9a69-d617-5823-87e8-5b366556a387
DOI: 10.22541/au.166563547.79282253/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in severe asthma patients eligible for bothDOI 10.22541/au.166563547.79282253/v1Read

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read

Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthmaSemantic proximity Read

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity Read

Anti-interleukin-5 therapy in severe asthma.Semantic proximity Read

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read

[THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].Semantic proximity Read

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease: A Narrative ReviewSemantic proximity Read

Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.Semantic proximity Read

Eosinophil Counts in Adults with Asthma Treated with Anti-IL-4Rα Rademikibart in a Randomized TrialSemantic proximity Read

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic PhenotypeSemantic proximity Read

¿p#1 Multidomain Clinical and Biological Remission with Tezepelumab in Severe Asthma: A 12-Month Multicentre Real-World StudySemantic proximity Read